Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis.

Pitt B, Rossignol P.

J Am Coll Cardiol. 2014 Feb 18;63(6):537-8. doi: 10.1016/j.jacc.2013.09.057. Epub 2013 Oct 30. No abstract available.

2.

Effect of spironolactone in CV mortality in hemodialysis patients.

Kannan A, Poongkunran C, Balamuthusamy S.

J Am Coll Cardiol. 2014 Aug 5;64(5):528-9. doi: 10.1016/j.jacc.2014.03.053. No abstract available.

3.

Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.

Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, Yakushigawa T, Sugiyama H, Shimada Y, Nojima Y, Shio N.

J Am Coll Cardiol. 2014 Feb 18;63(6):528-36. doi: 10.1016/j.jacc.2013.09.056. Epub 2013 Oct 30.

4.

Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis.

Baker WL, White WB.

Ann Pharmacother. 2012 Jun;46(6):889-94. doi: 10.1345/aph.1R011. Epub 2012 Jun 5. Review.

PMID:
22669801
5.

Aldosterone blockade and vascular calcification in hemodialysis patients.

Nitta K, Akiba T, Nihei H.

Am J Med. 2003 Aug 15;115(3):250. No abstract available.

PMID:
12935835
6.

Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: a systematic review and meta-analysis.

Zhao Y, Yan B, Zhao Z, Wang S, Weng X.

Ren Fail. 2016;38(4):589-99. doi: 10.3109/0886022X.2016.1149684. Epub 2016 Feb 24. Review.

PMID:
26905224
7.

Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial.

Ng KP, Jain P, Heer G, Redman V, Chagoury OL, Dowswell G, Greenfield S, Freemantle N, Townend JN, Gill PS, McManus RJ, Ferro CJ.

Trials. 2014 May 6;15:158. doi: 10.1186/1745-6215-15-158.

8.

Aldosterone receptor blockade and the role of eplerenone: evolving perspectives.

Epstein M.

Nephrol Dial Transplant. 2003 Oct;18(10):1984-92. Review. No abstract available.

PMID:
13679471
9.

How is the heart best protected in chronic dialysis patients?: Is there life in the old drugs yet? Mineralocorticoid receptor antagonism for cardiovascular prevention in chronic dialysis patients.

Mark PB, Taylor AH, McQuarrie EP, Jardine AG.

Semin Dial. 2014 Jul-Aug;27(4):328-32. doi: 10.1111/sdi.12178. Epub 2014 Feb 5. Review. No abstract available.

PMID:
24499322
10.

Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End-Stage Renal Disease: New Data But the Controversy Continues.

Georgianos PI, Sarafidis PA, Liakopoulos V, Balaskas EV, Zebekakis PE.

J Clin Hypertens (Greenwich). 2016 Mar;18(3):197-9. doi: 10.1111/jch.12718. Epub 2015 Oct 12. No abstract available.

11.

Eplerenone's role in the management of complex cardiovascular disorders.

Stewart Coats AJ, Shewan L.

Int J Cardiol. 2015 Dec 1;200:1-2. doi: 10.1016/j.ijcard.2015.05.128. Epub 2015 May 21. Review.

PMID:
26116081
12.

Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?

Chua D, Lo A, Lo C.

Clin Cardiol. 2010 Oct;33(10):604-8. doi: 10.1002/clc.20838. Review.

13.

Mineralocorticoid receptor blockade in the protection of target organ damage.

Mulatero P, Milan A, Williams TA, Veglio F.

Cardiovasc Hematol Agents Med Chem. 2006 Jan;4(1):75-91. Review.

PMID:
16529552
14.

Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease.

Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P, Nowack C, Kolkhof P, Kim SY, Zannad F.

Eur J Heart Fail. 2012 Jun;14(6):668-75. doi: 10.1093/eurjhf/hfs061. Epub 2012 May 4.

15.

Eplerenone: cardiovascular protection.

Brown NJ.

Circulation. 2003 May 20;107(19):2512-8. Review.

16.

The role of aldosterone receptor blockade in the management of cardiovascular disease.

Liew D, Krum H.

Curr Opin Investig Drugs. 2002 Oct;3(10):1468-73. Review.

PMID:
12431020
17.

[The use of aldosterone antagonists in the cardiovascular diseases].

Trzaska E, Gumułka W, Makulska-Nowak HE.

Kardiol Pol. 2009 Jun;67(6):667-71. Review. Polish. No abstract available.

18.

Aldosterone antagonists--last man standing?

Armstrong PW.

N Engl J Med. 2011 Jan 6;364(1):79-80. doi: 10.1056/NEJMe1012547. Epub 2010 Nov 14. No abstract available.

PMID:
21073364
19.

Eplerenone in mild heart failure.

Tomaschitz A, Pilz S, März W.

N Engl J Med. 2011 Apr 7;364(14):1371; author reply 1372. doi: 10.1056/NEJMc1101287#SA3. No abstract available.

PMID:
21470018
20.

Eplerenone in mild heart failure.

Gus M, Fuchs FD.

N Engl J Med. 2011 Apr 7;364(14):1370-1; author reply 1372. doi: 10.1056/NEJMc1101287#SA2. No abstract available.

PMID:
21470019

Supplemental Content

Support Center